Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib vs Celecoxib in Knee Osteoarthritis
NCT00092365Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2003
- Primary completion
- Nov 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rofecoxib in knee osteoarthritis (OA) (3 arms), sponsored by Merck & Co. Primary endpoints: Patient Global Assessment of Response to Therapy at 6 weeks and Western Ontario and McMaster Universities Osteoarthritis Index VA 3.0 at 6 weeks. Started Apr 2003; status: completed.
02
Drugs
rofecoxib
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00092365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092365.